Related Experiment Video

Updated: Feb 26, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

5.2K

GSK-3β inhibition suppresses instability-induced osteolysis by a dual action on osteoblast and osteoclast

Mehdi Amirhosseini1, Rune V Madsen2, K Jane Escott3

  • 1Division of Cell Biology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.

Journal of Cellular Physiology
|July 22, 2017
PubMed

Insights

Inhibiting glycogen synthase kinase-3β (GSK-3β) with AR28 promotes osteoblast differentiation and reduces osteoclast activity, thereby increasing bone mass and combating instability-induced osteolysis in orthopedic implants.

Area of Science:

  • Orthopedics
  • Biomaterials Science
  • Cell Biology

Background:

  • Aseptic loosening of orthopedic implants is a significant clinical problem with no current pharmacological treatments.
  • Osteolysis, or bone loss around implants, is driven by osteoclast activity and modulated by Wnt/β-catenin signaling.
  • Previous research utilized osteoprotegerin fusion protein (OPG-Fc) to inhibit osteoclast differentiation and peri-implant osteolysis.

Purpose of the Study:

  • To investigate the potential of inhibiting glycogen synthase kinase-3β (GSK-3β) to modulate Wnt/β-catenin signaling and reduce instability-induced bone loss.
  • To examine the effects of GSK-3β inhibition on osteoblast and osteoclast differentiation in a rat model of mechanical instability-induced peri-implant osteolysis.

Main Methods:

  • Rats with mechanical instability-induced peri-implant osteolysis were treated daily with a GSK-3β inhibitor, AR28.
  • Gene expression (qRT-PCR), protein levels (immunohistochemistry, ELISA), and bone microarchitecture (micro-CT) were assessed.
  • Key markers for osteoblast differentiation (β-catenin, Runx2, Osterix, Col1α1, ALP) and osteoclast activity (RANKL, OPG, TRAP5b) were analyzed.

Main Results:

  • AR28 treatment upregulated osteoblast differentiation markers and increased osteoblast numbers.
  • GSK-3β inhibition rescued mechanical instability-induced downregulation of BMP-2 and Wnt16.
  • Osteoclast numbers and serum TRAP5b levels were significantly decreased, correlating with enhanced OPG expression.

Conclusions:

  • GSK-3β inactivation by AR28 promotes osteoblast differentiation and suppresses osteoclastogenesis.
  • This dual action leads to increased bone mass and suppression of osteolysis in a preclinical model.
  • Targeting GSK-3β represents a potential therapeutic strategy for preventing or treating aseptic loosening of orthopedic implants.
Keywords:
GSK-3βWnt signalingbone implantmechanical instabilityosteolysis

More Related Videos

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments06:16

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

8.1K
Stimulation of Notch Signaling in Mouse Osteoclast Precursors08:01

Stimulation of Notch Signaling in Mouse Osteoclast Precursors

Published on: February 28, 2017

8.4K

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.4K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
4.0K
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.7K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.7K
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.7K